Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	5267	910463-68-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rybelsus semaglutide NNC 0113-0217 ozempic wegovy	Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. Molecular weight: 4113.64 Formula: C187H291N45O59 CLOGP: LIPINSKI: None HAC: 104 HDO: 57 TPSA: 1646.18 ALOGS: ROTB: 149

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rybelsus
semaglutide
NNC 0113-0217
ozempic
wegovy

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Molecular weight: 4113.64
Formula: C187H291N45O59
CLOGP:
LIPINSKI: None
HAC: 104
HDO: 57
TPSA: 1646.18
ALOGS:
ROTB: 149

Drug dosage:

Dose	Unit	Route
10.50	mg	O
0.11	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company
Feb. 8, 2018	EMA	Novo Nordisk A/S
March 23, 2018	PMDA	Novo Nordisk Pharma Ltd
Dec. 5, 2017	FDA	NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Optic ischaemic neuropathy	715.15	12.72	173	52974	1579	90573721
Pancreatitis	709.91	12.72	466	52681	69360	90505940
Nausea	692.04	12.72	1798	51349	1108518	89466782
Vomiting	568.77	12.72	1352	51795	786941	89788359
Diabetic ketoacidosis	457.12	12.72	242	52905	24165	90551135
Impaired gastric emptying	364.93	12.72	169	52978	12640	90562660
Euglycaemic diabetic ketoacidosis	296.36	12.72	118	53029	6083	90569217
Inappropriate schedule of product administration	263.46	12.72	379	52768	149554	90425746
Glycosylated haemoglobin increased	251.56	12.72	140	53007	15422	90559878
Counterfeit product administered	246.51	12.72	44	53103	58	90575242
Pancreatitis acute	229.72	12.72	173	52974	31942	90543358
Pancreatic carcinoma	227.68	12.72	107	53040	8270	90567030
Lactic acidosis	204.41	12.72	196	52951	50267	90525033
Dehydration	199.41	12.72	386	52761	194061	90381239
Hypoglycaemia	197.86	12.72	224	52923	69624	90505676
Product use in unapproved indication	197.27	12.72	535	52612	335701	90239599
Weight decreased	186.56	12.72	567	52580	379343	90195957
Cholelithiasis	184.97	12.72	189	52958	52317	90522983
Blood glucose increased	183.90	12.72	252	52895	94994	90480306
Obstructive pancreatitis	182.30	12.72	48	53099	633	90574667
Synovitis	178.22	12.72	3	53144	329749	90245551
Constipation	173.33	12.72	455	52692	279940	90295360
Glossodynia	162.32	12.72	6	53141	321773	90253527
Systemic lupus erythematosus	157.85	12.72	15	53132	361881	90213419
Arthropathy	147.66	12.72	20	53127	366222	90209078
Blood glucose decreased	145.30	12.72	116	53031	23313	90551987
Illness	145.01	12.72	208	52939	81761	90493539
Depressed mood	142.10	12.72	161	52986	50061	90525239
Suspected counterfeit product	140.44	12.72	37	53110	489	90574811
Wound	136.34	12.72	11	53136	302969	90272331
Ketoacidosis	135.42	12.72	66	53081	5529	90569771
Weight loss poor	134.62	12.72	45	53102	1400	90573900
Pericarditis	133.00	12.72	6	53141	270145	90305155
Product communication issue	132.94	12.72	45	53102	1456	90573844
Intestinal obstruction	125.96	12.72	131	53016	37000	90538300
Eructation	123.69	12.72	78	53069	10804	90564496
Thyroid mass	123.13	12.72	61	53086	5294	90570006
Joint swelling	120.63	12.72	73	53074	503227	90072073
Treatment failure	116.94	12.72	19	53128	303909	90271391
Biliary colic	116.93	12.72	54	53093	4009	90571291
Stomatitis	115.58	12.72	13	53134	274685	90300615
Suicidal ideation	114.24	12.72	176	52971	73679	90501621
Cholecystitis	111.32	12.72	87	53060	16953	90558347
Diabetic retinopathy	110.55	12.72	46	53101	2656	90572644
Vision blurred	109.36	12.72	216	52931	110077	90465223
Swelling	108.76	12.72	55	53092	419003	90156297
Dermatitis atopic	108.19	12.72	98	53049	23374	90551926
Starvation ketoacidosis	106.24	12.72	25	53122	200	90575100
Folliculitis	105.90	12.72	3	53144	204350	90370950
Impaired healing	103.97	12.72	9	53138	234190	90341110
Helicobacter infection	102.69	12.72	8	53139	226842	90348458
Decreased appetite	102.67	12.72	465	52682	376075	90199225
Injection site pain	101.26	12.72	276	52871	173423	90401877
Contraindicated product administered	101.14	12.72	31	53116	320108	90255192
Abdominal pain	99.31	12.72	477	52670	395244	90180056
Pneumonia	99.05	12.72	138	53009	637921	89937379
Hunger	97.82	12.72	56	53091	6507	90568793
Infusion related reaction	97.68	12.72	62	53085	416718	90158582
Medullary thyroid cancer	97.39	12.72	24	53123	238	90575062
Exposure during pregnancy	96.08	12.72	13	53134	238397	90336903
Drug ineffective	95.17	12.72	454	52693	1383844	89191456
Increased appetite	94.52	12.72	68	53079	11697	90563603
Wrong technique in product usage process	93.55	12.72	158	52989	71413	90503887
Lipase increased	93.37	12.72	66	53081	11045	90564255
Diarrhoea	90.94	12.72	894	52253	938296	89637004
COVID-19	88.34	12.72	258	52889	168585	90406715
Allodynia	87.94	12.72	30	53117	994	90574306
Retinopathy	86.46	12.72	42	53105	3492	90571808
Product dispensing error	85.27	12.72	65	53082	12208	90563092
General physical health deterioration	84.33	12.72	52	53095	355063	90220237
Therapeutic product effect decreased	83.92	12.72	29	53118	277542	90297758
Prescription drug used without a prescription	83.62	12.72	40	53107	3215	90572085
Death	83.25	12.72	87	53060	456464	90118836
Colitis ischaemic	80.57	12.72	63	53084	12283	90563017
Fibromyalgia	79.08	12.72	13	53134	206256	90369044
Papillary thyroid cancer	79.00	12.72	36	53111	2591	90572709
Food craving	78.84	12.72	33	53114	1934	90573366
Blindness	76.55	12.72	86	53061	26482	90548818
Sleep disorder due to a general medical condition	75.41	12.72	111	53036	44627	90530673
Drug intolerance	72.22	12.72	94	53053	447497	90127803
Blindness unilateral	72.16	12.72	49	53098	7687	90567613
Heart sounds	69.77	12.72	26	53121	1118	90574182
Depressive symptom	67.99	12.72	41	53106	5244	90570056
Abnormal loss of weight	67.92	12.72	45	53102	6778	90568522
Drug dose titration not performed	67.80	12.72	23	53124	749	90574551
Prolonged expiration	67.38	12.72	26	53121	1231	90574069
Neutropenia	65.42	12.72	25	53122	224879	90350421
Blister	65.30	12.72	34	53113	254964	90320336
Pyrexia	65.28	12.72	186	52961	660299	89915001
Confusional state	64.48	12.72	79	53068	386126	90189174
Drug hypersensitivity	64.42	12.72	108	53039	463501	90111799
Irritable bowel syndrome	63.86	12.72	21	53126	207427	90367873
Musculoskeletal stiffness	62.98	12.72	49	53098	296483	90278817
Diabetes mellitus inadequate control	61.71	12.72	65	53082	18619	90556681
Anaemia	61.21	12.72	70	53077	352732	90222568
Drug titration error	60.71	12.72	24	53123	1213	90574087
Throat clearing	60.50	12.72	34	53113	3813	90571487
Disease progression	59.73	12.72	10	53137	156605	90418695
Hypersensitivity	58.59	12.72	111	53036	454566	90120734
Oedema	57.04	12.72	23	53124	200272	90375028
Glomerular filtration rate decreased	56.09	12.72	59	53088	16873	90558427
Musculoskeletal pain	55.10	12.72	16	53131	171235	90404065
Nasal congestion	54.12	12.72	138	53009	83276	90492024
Post cholecystectomy syndrome	53.64	12.72	20	53127	861	90574439
Liver injury	52.96	12.72	17	53130	170550	90404750
Off label use	52.56	12.72	922	52225	1101330	89473970
Mobility decreased	52.52	12.72	42	53105	250692	90324608
Oedema peripheral	51.80	12.72	45	53102	257870	90317430
Mesenteric panniculitis	51.75	12.72	14	53133	206	90575094
Product dose omission in error	51.74	12.72	62	53085	20441	90554859
Pancreatitis necrotising	51.43	12.72	26	53121	2355	90572945
Stress	51.09	12.72	133	53014	81262	90494038
Cholecystitis acute	50.84	12.72	43	53104	9361	90565939
Thrombocytopenia	50.30	12.72	30	53117	208695	90366605
Toxicity to various agents	50.04	12.72	57	53090	287789	90287511
C3 glomerulopathy	49.90	12.72	13	53134	164	90575136
Rheumatoid arthritis	48.94	12.72	86	53061	362528	90212772
Vitamin B12 increased	48.62	12.72	23	53124	1803	90573497
Cholecystectomy	48.22	12.72	46	53101	11709	90563591
Ketosis	47.93	12.72	18	53129	791	90574509
Infection	47.86	12.72	87	53060	362007	90213293
Ill-defined disorder	46.81	12.72	25	53122	184866	90390434
Gait inability	46.54	12.72	14	53133	146442	90428858
Glomerular filtration rate increased	45.98	12.72	23	53124	2037	90573263
Osteoarthritis	45.95	12.72	29	53118	195701	90379599
Incorrect dose administered	45.53	12.72	125	53022	78805	90496495
Malignant neoplasm progression	45.06	12.72	5	53142	106865	90468435
Bursitis	44.81	12.72	11	53136	131643	90443657
Febrile neutropenia	43.77	12.72	19	53128	158330	90416970
Skin laxity	43.42	12.72	10	53137	72	90575228
Myoglobinuria	43.14	12.72	14	53133	396	90574904
Blood immunoglobulin A increased	43.11	12.72	19	53128	1264	90574036
Pulmonary fibrosis	42.96	12.72	6	53141	107497	90467803
Diabetic ketosis	42.63	12.72	15	53132	546	90574754
Postmenopausal haemorrhage	42.40	12.72	23	53124	2407	90572893
Wound infection	42.38	12.72	6	53141	106396	90468904
Hypercholesterolaemia	41.84	12.72	5	53142	100887	90474413
Visual impairment	41.76	12.72	171	52976	132194	90443106
Lung disorder	41.40	12.72	18	53129	149865	90425435
Delirium	41.29	12.72	6	53141	104353	90470947
Electric shock	40.73	12.72	20	53127	1702	90573598
Bile duct stone	40.67	12.72	27	53120	4080	90571220
Granulocyte count increased	39.86	12.72	19	53128	1515	90573785
Surgery	39.83	12.72	84	53063	44803	90530497
Blood cholesterol increased	39.73	12.72	38	53109	207974	90367326
Facial wasting	39.31	12.72	7	53140	9	90575291
Respiration abnormal	38.18	12.72	34	53113	7929	90567371
Sensitive skin	37.83	12.72	24	53123	3357	90571943
Injection site discharge	37.79	12.72	18	53129	1433	90573867
Psoriatic arthropathy	37.77	12.72	47	53100	228288	90347012
Completed suicide	37.63	12.72	19	53128	145039	90430261
Hepatic enzyme increased	37.49	12.72	99	53048	360637	90214663
Urine protein/creatinine ratio increased	37.31	12.72	16	53131	996	90574304
Pancytopenia	37.31	12.72	12	53135	120251	90455049
Respiratory failure	36.41	12.72	12	53135	118406	90456894
Feeding disorder	36.30	12.72	48	53099	17464	90557836
Product availability issue	36.27	12.72	32	53115	7372	90567928
Peripheral swelling	36.02	12.72	123	53024	412983	90162317
Flank pain	35.77	12.72	50	53097	19172	90556128
Prescribed overdose	35.56	12.72	7	53140	97618	90477682
Gastrointestinal disorder	35.53	12.72	265	52882	256422	90318878
Live birth	35.19	12.72	3	53144	79104	90496196
Distributive shock	35.10	12.72	23	53124	3401	90571899
Leukopenia	35.09	12.72	8	53139	100702	90474598
Flatulence	35.07	12.72	76	53071	41291	90534009
Aspartate aminotransferase	34.98	12.72	14	53133	731	90574569
Thyroid cancer	34.52	12.72	29	53118	6255	90569045
Palpitations	34.32	12.72	165	52982	136563	90438737
Appetite disorder	34.20	12.72	34	53113	9099	90566201
Vomiting projectile	34.03	12.72	18	53129	1791	90573509
Exposure via skin contact	33.16	12.72	36	53111	10669	90564631
Throat irritation	33.08	12.72	82	53065	48613	90526687
Grip strength decreased	32.97	12.72	7	53140	92569	90482731
Food aversion	32.84	12.72	16	53131	1339	90573961
Discomfort	32.71	12.72	70	53077	274265	90301035
Vitreous detachment	32.02	12.72	19	53128	2359	90572941
Vaccination site pain	31.81	12.72	11	53136	380	90574920
Rheumatoid factor increased	31.78	12.72	19	53128	2392	90572908
Hyperthyroidism	31.68	12.72	46	53101	18264	90557036
Abdominal distension	31.63	12.72	156	52991	130445	90444855
Acute kidney injury	30.30	12.72	304	52843	320083	90255217
Menstruation irregular	30.17	12.72	30	53117	8030	90567270
Diabetic metabolic decompensation	29.97	12.72	17	53130	1940	90573360
Depression suicidal	29.25	12.72	17	53130	2032	90573268
Irregular sleep phase	29.01	12.72	6	53141	24	90575276
Night sweats	28.97	12.72	20	53127	128746	90446554
Impaired quality of life	28.78	12.72	50	53097	23094	90552206
Post-traumatic stress disorder	28.54	12.72	27	53120	6801	90568499
Inflammation	28.25	12.72	38	53109	178554	90396746
Prescribed underdose	28.14	12.72	5	53142	75014	90500286
Productive cough	27.91	12.72	104	53043	76959	90498341
Abortion spontaneous	27.66	12.72	82	53065	53974	90521326
Dizziness	27.59	12.72	492	52655	588792	89986508
Hospitalisation	27.53	12.72	148	52999	127952	90447348
Haemoglobin decreased	27.13	12.72	33	53114	161923	90413377
Nephrolithiasis	26.59	12.72	76	53071	49009	90526291
Incorrect dose administered by device	26.52	12.72	24	53123	5713	90569587
Asthma	26.48	12.72	237	52910	241923	90333377
Dry skin	26.38	12.72	112	53035	87961	90487339
Ileus	26.37	12.72	40	53107	16506	90558794
Vascular stent stenosis	25.95	12.72	11	53136	665	90574635
Drug abuse	25.92	12.72	8	53139	82339	90492961
Epilepsy	25.85	12.72	8	53139	82198	90493102
Dactylitis	25.78	12.72	20	53127	3853	90571447
Syncope	25.67	12.72	149	52998	132514	90442786
Vaginal haemorrhage	24.87	12.72	56	53091	31215	90544085
Papilloedema	24.74	12.72	21	53126	4594	90570706
Foot deformity	24.62	12.72	3	53144	59648	90515652
Pain	24.57	12.72	424	52723	995917	89579383
Intentional product use issue	24.49	12.72	57	53090	216835	90358465
Eye haemorrhage	24.41	12.72	30	53117	10150	90565150
Nail disorder	24.31	12.72	3	53144	59064	90516236
Joint noise	24.20	12.72	22	53125	5268	90570032
Cardio-respiratory arrest	24.14	12.72	4	53143	63136	90512164
Intussusception	24.09	12.72	12	53135	1053	90574247
Cardiac failure congestive	24.03	12.72	14	53133	98680	90476620
Small intestinal obstruction	24.00	12.72	44	53103	21190	90554110
Product administration interrupted	24.00	12.72	33	53114	12459	90562841
Optic neuritis	23.98	12.72	29	53118	9649	90565651
Diabetes mellitus	23.86	12.72	88	53059	64787	90510513
Hyperlipasaemia	23.77	12.72	11	53136	820	90574480
Extra dose administered	23.71	12.72	28	53119	9090	90566210
Sinusitis	23.66	12.72	112	53035	342976	90232324
Gallbladder disorder	23.62	12.72	42	53105	19761	90555539
Pregnancy on oral contraceptive	23.57	12.72	12	53135	1103	90574197
Diverticulitis	23.55	12.72	69	53078	45118	90530182
Rales	23.46	12.72	37	53110	15790	90559510
Liver disorder	23.33	12.72	22	53125	121247	90454053
Intervertebral discitis	23.07	12.72	20	53127	4500	90570800
Inner ear operation	23.00	12.72	4	53143	4	90575296
Vitreous haemorrhage	23.00	12.72	16	53131	2610	90572690
Injury	22.98	12.72	51	53096	197298	90378002
Influenza	22.91	12.72	150	52997	139114	90436186
Vitamin B12 deficiency	22.88	12.72	25	53122	7461	90567839
Idiopathic intracranial hypertension	22.77	12.72	18	53129	3563	90571737
Hypertension	22.70	12.72	166	52981	457366	90117934
C-reactive protein increased	22.70	12.72	45	53102	181344	90393956
Abdominal pain upper	22.59	12.72	296	52851	332378	90242922
Sciatica	22.47	12.72	16	53131	101366	90473934
Blepharospasm	22.37	12.72	3	53144	55442	90519858
Benign pancreatic neoplasm	22.22	12.72	5	53142	32	90575268
Oropharyngeal pain	22.04	12.72	129	53018	115058	90460242
Adverse event	21.78	12.72	22	53125	117396	90457904
Osteoporosis	21.70	12.72	15	53132	96516	90478784
Hyperaesthesia	21.67	12.72	29	53118	10673	90564627
Device leakage	21.66	12.72	28	53119	9963	90565337
Macular oedema	21.65	12.72	20	53127	4889	90570411
Alopecia	21.61	12.72	186	52961	494885	90080415
Myelosuppression	21.39	12.72	3	53144	53588	90521712
Maculopathy	21.32	12.72	15	53132	2491	90572809
White blood cell count decreased	21.30	12.72	41	53106	167068	90408232
Retinal detachment	21.23	12.72	23	53124	6799	90568501
Pancreatic disorder	21.22	12.72	16	53131	2955	90572345
Blood glucose abnormal	21.21	12.72	27	53120	9465	90565835
Urinary incontinence	21.17	12.72	59	53088	37507	90537793
Lipoma	21.15	12.72	16	53131	2970	90572330
Appendicitis	21.14	12.72	28	53119	10203	90565097
Sleep apnoea syndrome	21.08	12.72	53	53094	31694	90543606
Blindness transient	20.99	12.72	19	53128	4524	90570776
Hiccups	20.96	12.72	16	53131	3010	90572290
Polymenorrhoea	20.87	12.72	12	53135	1405	90573895
Lower limb fracture	20.78	12.72	12	53135	85001	90490299
Aspartate aminotransferase abnormal	20.57	12.72	15	53132	2634	90572666
Amylase increased	20.55	12.72	23	53124	7049	90568251
Upper-airway cough syndrome	20.55	12.72	34	53113	15101	90560199
Pancreatic failure	20.30	12.72	12	53135	1480	90573820
Injection site vesicles	20.27	12.72	18	53129	4182	90571118
Depression	20.21	12.72	267	52880	300334	90274966
Adenocarcinoma pancreas	20.16	12.72	11	53136	1165	90574135
Injection site bruising	20.12	12.72	72	53075	52235	90523065
Skin exfoliation	20.05	12.72	86	53061	67827	90507473
Autoimmune disorder	19.97	12.72	10	53137	76734	90498566
Sunburn	19.88	12.72	16	53131	3251	90572049
Glycosylated haemoglobin decreased	19.85	12.72	9	53138	640	90574660
Idiopathic angioedema	19.82	12.72	5	53142	55	90575245
Hypophagia	19.81	12.72	56	53091	35881	90539419
Hyperphagia	19.74	12.72	15	53132	2803	90572497
Hip arthroplasty	19.73	12.72	10	53137	76198	90499102
Glycosylated haemoglobin abnormal	19.66	12.72	7	53140	264	90575036
Cholelithotomy	19.50	12.72	5	53142	59	90575241
Contraindicated product prescribed	19.37	12.72	12	53135	1610	90573690
Pigmentation lip	19.33	12.72	3	53144	0	90575300
Therapy interrupted	19.30	12.72	69	53078	50039	90525261
Diabetic neuropathy	18.95	12.72	18	53129	4556	90570744
Skin burning sensation	18.93	12.72	38	53109	19573	90555727
Platelet count decreased	18.89	12.72	32	53115	136937	90438363
Therapeutic product effect incomplete	18.79	12.72	55	53092	193841	90381459
Colitis	18.71	12.72	86	53061	69856	90505444
Myalgia	18.42	12.72	170	52977	174955	90400345
Fungal infection	18.40	12.72	61	53086	42600	90532700
Loss of consciousness	18.38	12.72	143	53004	140095	90435205
Eyelid injury	18.38	12.72	6	53141	173	90575127
Carpal tunnel decompression	18.20	12.72	10	53137	1073	90574227
Intentional dose omission	17.81	12.72	35	53112	17748	90557552
Urethral caruncle	17.75	12.72	5	53142	86	90575214
Paranasal sinus discomfort	17.71	12.72	20	53127	6190	90569110
Blood ketone body increased	17.70	12.72	7	53140	354	90574946
Eyelid haematoma	17.70	12.72	5	53142	87	90575213
Monocyte count increased	17.43	12.72	24	53123	9073	90566227
Gait disturbance	17.39	12.72	86	53061	260410	90314890
Pancreatic enzymes increased	17.34	12.72	9	53138	861	90574439
Pharyngeal swelling	17.23	12.72	25	53122	9919	90565381
Retinal haemorrhage	17.19	12.72	19	53128	5745	90569555
Device malfunction	17.17	12.72	38	53109	20939	90554361
Obesity	17.14	12.72	22	53125	105485	90469815
Terminal insomnia	17.13	12.72	10	53137	1205	90574095
Neuroendocrine tumour	17.05	12.72	9	53138	892	90574408
Hepatic steatosis	16.99	12.72	54	53093	36891	90538409
White blood cells urine positive	16.97	12.72	20	53127	6478	90568822
Food interaction	16.76	12.72	10	53137	1254	90574046
Product dose omission issue	16.75	12.72	252	52895	291435	90283865
Contusion	16.74	12.72	83	53064	251133	90324167
High frequency ablation	16.68	12.72	6	53141	233	90575067
Product substitution error	16.48	12.72	4	53143	37	90575263
Urine calcium/creatinine ratio increased	16.27	12.72	5	53142	118	90575182
Menstrual disorder	16.21	12.72	19	53128	6119	90569181
Hyperglycaemia	16.18	12.72	66	53081	50904	90524396
Injection site extravasation	16.10	12.72	23	53124	8996	90566304
Volvulus	16.04	12.72	12	53135	2191	90573109
Transient lingual papillitis	16.03	12.72	3	53144	6	90575294
Device programming error	15.99	12.72	6	53141	263	90575037
Blood uric acid increased	15.79	12.72	21	53126	7683	90567617
Fluid retention	15.78	12.72	17	53130	88074	90487226
Interstitial lung disease	15.73	12.72	13	53134	76392	90498908
Hyperhidrosis	15.71	12.72	135	53012	136170	90439130
Underdose	15.70	12.72	6	53141	54011	90521289
Product packaging difficult to open	15.70	12.72	5	53142	133	90575167
Blood pressure systolic decreased	15.62	12.72	23	53124	9247	90566053
Abdominal discomfort	15.61	12.72	192	52955	477136	90098164
Sudden visual loss	15.46	12.72	4	53143	49	90575251
Bradycardia	15.22	12.72	16	53131	83831	90491469
Pancreatic carcinoma metastatic	15.18	12.72	12	53135	2376	90572924
Angina pectoris	15.15	12.72	54	53093	39106	90536194
Hypoglycaemic unconsciousness	15.03	12.72	8	53139	806	90574494
Therapeutic response shortened	14.98	12.72	38	53109	22841	90552459
Hypoacusis	14.97	12.72	43	53104	27807	90547493
Eczema	14.88	12.72	66	53081	52804	90522496
Pregnancy	14.82	12.72	9	53138	62038	90513262
Heart rate increased	14.73	12.72	115	53032	112787	90462513
Pleural effusion	14.69	12.72	27	53120	111964	90463336
Steatorrhoea	14.65	12.72	7	53140	561	90574739
Joint dislocation	14.64	12.72	4	53143	44578	90530722
Neutrophil count increased	14.62	12.72	34	53113	19356	90555944
Vitamin D deficiency	14.59	12.72	32	53115	17524	90557776
Sarcopenia	14.57	12.72	6	53141	337	90574963
Pancreatic mass	14.57	12.72	9	53138	1202	90574098
Retinal vein occlusion	14.46	12.72	12	53135	2544	90572756
Thyroid hormones increased	14.40	12.72	7	53140	583	90574717
Hepatitis toxic	14.19	12.72	14	53133	3711	90571589
Injection site reaction	14.15	12.72	20	53127	92060	90483240
Blood creatine phosphokinase increased	14.10	12.72	48	53099	33975	90541325
Lack of injection site rotation	14.02	12.72	8	53139	923	90574377
Pregnancy on contraceptive	14.01	12.72	9	53138	1286	90574014
Immunodeficiency	13.97	12.72	4	53143	43230	90532070
Decreased interest	13.96	12.72	15	53132	4392	90570908
Ileus paralytic	13.86	12.72	16	53131	5069	90570231
Pancreatic cyst	13.82	12.72	11	53136	2199	90573101
Arthritis	13.77	12.72	51	53096	167264	90408036
Foreign body sensation in eyes	13.70	12.72	13	53134	3287	90572013
Blood ketone body present	13.68	12.72	4	53143	79	90575221
Injection site haemorrhage	13.58	12.72	42	53105	28276	90547024
Symptom recurrence	13.48	12.72	14	53133	3945	90571355
Hepatotoxicity	13.48	12.72	5	53142	45837	90529463
Demyelination	13.43	12.72	20	53127	8120	90567180
Orthopaedic procedure	13.42	12.72	5	53142	215	90575085
Diabetic retinal oedema	13.38	12.72	6	53141	416	90574884
Early satiety	13.33	12.72	9	53138	1398	90573902
Colon cancer stage II	13.26	12.72	5	53142	222	90575078
Therapy non-responder	13.08	12.72	39	53108	136665	90438635
Reperfusion arrhythmia	13.01	12.72	5	53142	234	90575066
Joint stiffness	12.96	12.72	16	53131	78026	90497274
Head injury	12.92	12.72	44	53103	31144	90544156
Intermenstrual bleeding	12.90	12.72	21	53126	9202	90566098
Lower respiratory tract infection	12.87	12.72	90	53057	250569	90324731
Dry mouth	12.73	12.72	60	53087	183999	90391301

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatitis	890.55	14.42	471	27080	42797	42550987
Optic ischaemic neuropathy	745.31	14.42	200	27351	2575	42591209
Vomiting	744.84	14.42	922	26629	288801	42304983
Nausea	646.89	14.42	1014	26537	395785	42197999
Euglycaemic diabetic ketoacidosis	381.55	14.42	142	27409	5518	42588266
Diabetic ketoacidosis	263.87	14.42	170	27381	22197	42571587
Diarrhoea	260.34	14.42	767	26784	460082	42133702
Impaired gastric emptying	235.01	14.42	93	27458	4273	42589511
Weight decreased	196.72	14.42	422	27129	207526	42386258
Pancreatic carcinoma	193.69	14.42	103	27448	9403	42584381
Eructation	185.52	14.42	84	27467	5402	42588382
Glycosylated haemoglobin increased	146.89	14.42	96	27455	12828	42580956
Decreased appetite	132.44	14.42	346	27205	192791	42400993
Gastrointestinal disorder	127.54	14.42	154	27397	46499	42547285
Pancreatitis acute	122.87	14.42	129	27422	33435	42560349
Cholelithiasis	121.77	14.42	109	27442	23237	42570547
Cholecystitis acute	105.22	14.42	64	27487	7542	42586242
Abdominal pain	100.94	14.42	311	27240	190160	42403624
Inappropriate schedule of product administration	94.26	14.42	198	27353	95704	42498080
Obstructive pancreatitis	94.06	14.42	30	27521	725	42593059
Diabetic retinopathy	94.01	14.42	39	27512	2024	42591760
Neutropenia	91.09	14.42	11	27540	199420	42394364
Retinopathy	90.24	14.42	39	27512	2242	42591542
Pneumonia	89.39	14.42	85	27466	422064	42171720
Blood glucose increased	85.39	14.42	163	27388	73536	42520248
Bile duct stone	84.76	14.42	40	27511	2827	42590957
Pancreatitis necrotising	84.22	14.42	43	27508	3606	42590178
Ketoacidosis	81.74	14.42	48	27503	5304	42588480
Dehydration	81.18	14.42	238	27313	141529	42452255
Abdominal distension	81.07	14.42	157	27394	71578	42522206
Constipation	80.41	14.42	259	27292	162032	42431752
Anaemia	79.61	14.42	41	27510	280237	42313547
Medullary thyroid cancer	73.44	14.42	15	27536	49	42593735
Lactic acidosis	70.44	14.42	114	27437	45147	42548637
Allodynia	68.44	14.42	26	27525	1068	42592716
Suicidal ideation	66.53	14.42	115	27436	48046	42545738
Death	64.46	14.42	130	27421	471055	42122729
Flatulence	63.81	14.42	80	27471	25072	42568712
Diabetes mellitus inadequate control	63.28	14.42	63	27488	15327	42578457
Febrile neutropenia	62.61	14.42	21	27530	185682	42408102
Oedematous pancreatitis	62.11	14.42	22	27529	739	42593045
Vision blurred	61.22	14.42	118	27433	53581	42540203
Drug ineffective	60.97	14.42	207	27344	629990	41963794
Abdominal discomfort	60.00	14.42	143	27408	75112	42518672
Gastrooesophageal reflux disease	58.93	14.42	105	27446	44918	42548866
Visual impairment	55.73	14.42	100	27451	43013	42550771
Blood glucose decreased	54.43	14.42	56	27495	14163	42579621
Thrombocytopenia	53.72	14.42	28	27523	190251	42403533
Blindness unilateral	51.59	14.42	36	27515	5352	42588432
Pancreatic carcinoma metastatic	49.94	14.42	29	27522	3137	42590647
Cholecystitis	49.44	14.42	51	27500	12937	42580847
Malignant neoplasm progression	49.40	14.42	6	27545	108394	42485390
Toxicity to various agents	48.52	14.42	46	27505	229090	42364694
Abdominal pain upper	48.47	14.42	140	27411	82469	42511315
Pancytopenia	47.98	14.42	9	27542	117734	42476050
Hypoglycaemia	46.90	14.42	113	27438	59741	42534043
Product use in unapproved indication	46.69	14.42	239	27312	184217	42409567
Dizziness	45.48	14.42	296	27255	248958	42344826
Glomerular filtration rate decreased	44.68	14.42	54	27497	16297	42577487
Glycosylated haemoglobin decreased	44.54	14.42	15	27536	432	42593352
Intestinal obstruction	44.43	14.42	70	27481	27088	42566696
Disease progression	43.81	14.42	19	27532	143637	42450147
Lipase increased	42.97	14.42	43	27508	10523	42583261
Drug dose titration not performed	41.64	14.42	14	27537	401	42593383
Glycosylated haemoglobin abnormal	41.53	14.42	13	27538	295	42593489
Substance use	41.47	14.42	21	27530	1730	42592054
Acute kidney injury	40.89	14.42	389	27162	366948	42226836
Product communication issue	40.74	14.42	18	27533	1091	42592693
Respiratory failure	40.60	14.42	16	27535	128116	42465668
Platelet count decreased	39.68	14.42	20	27531	138561	42455223
Cellulitis gangrenous	38.47	14.42	12	27539	269	42593515
Cholecystectomy	38.17	14.42	25	27526	3349	42590435
Weight loss poor	37.03	14.42	11	27540	208	42593576
Pyrexia	36.22	14.42	132	27419	393910	42199874
Blindness	36.08	14.42	51	27500	17927	42575857
Pleural effusion	34.49	14.42	10	27541	97156	42496628
Hiccups	32.93	14.42	40	27511	12131	42581653
Sensitive skin	32.73	14.42	16	27535	1222	42592562
Abnormal loss of weight	31.51	14.42	26	27525	4961	42588823
Erectile dysfunction	31.18	14.42	57	27494	24856	42568928
Onychoclasis	30.86	14.42	20	27531	2632	42591152
Pancreatic enlargement	30.40	14.42	9	27542	168	42593616
Vitreous haemorrhage	30.21	14.42	20	27531	2727	42591057
Counterfeit product administered	29.82	14.42	10	27541	284	42593500
Hospitalisation	29.23	14.42	110	27441	74220	42519564
Illness	28.66	14.42	55	27496	24875	42568909
General physical health deterioration	27.93	14.42	34	27517	151212	42442572
Ketosis	27.90	14.42	13	27538	892	42592892
Biliary colic	27.69	14.42	14	27537	1150	42592634
Adenocarcinoma pancreas	27.11	14.42	15	27536	1479	42592305
Dyspepsia	27.11	14.42	73	27478	41279	42552505
Retching	26.72	14.42	29	27522	7792	42585992
Mesenteric panniculitis	26.62	14.42	10	27541	398	42593386
Leukopenia	25.96	14.42	8	27543	74738	42519046
Anion gap abnormal	25.95	14.42	10	27541	427	42593357
Drug abuse	25.92	14.42	18	27533	104753	42489031
Injection site pain	25.66	14.42	89	27462	57709	42536075
Neutrophil count decreased	25.50	14.42	5	27546	63410	42530374
Haemoglobin decreased	25.29	14.42	29	27522	132442	42461342
Small intestinal obstruction	25.21	14.42	42	27509	17019	42576765
Multiple organ dysfunction syndrome	24.91	14.42	16	27535	97019	42496765
Dermatitis atopic	24.61	14.42	35	27516	12369	42581415
Abdominal wall disorder	24.26	14.42	7	27544	119	42593665
Food aversion	24.25	14.42	10	27541	511	42593273
Food craving	24.06	14.42	10	27541	521	42593263
Oesophageal pain	23.41	14.42	12	27539	1014	42592770
Completed suicide	23.30	14.42	17	27534	96448	42497336
Hypoxia	23.30	14.42	8	27543	69778	42524006
Nephrolithiasis	23.13	14.42	64	27487	36766	42557018
Wrong technique in product usage process	22.84	14.42	70	27481	42565	42551219
Mycobacterium ulcerans infection	22.36	14.42	6	27545	77	42593707
Necrotising myositis	22.21	14.42	12	27539	1129	42592655
Thyroid cancer	22.12	14.42	14	27537	1769	42592015
Product label confusion	22.11	14.42	8	27543	286	42593498
White blood cell count decreased	21.25	14.42	24	27527	110372	42483412
Pancreatic mass	21.16	14.42	11	27540	957	42592827
Pancreatitis chronic	21.15	14.42	15	27536	2287	42591497
Plasma cell myeloma	20.79	14.42	3	27548	47575	42546209
Neuropathy vitamin B12 deficiency	20.74	14.42	7	27544	203	42593581
Hunger	20.72	14.42	14	27537	1974	42591810
Drug titration error	20.65	14.42	10	27541	748	42593036
Umbilical hernia repair	20.24	14.42	5	27546	45	42593739
Pancreatic failure	19.96	14.42	11	27540	1076	42592708
Pharyngeal swelling	19.95	14.42	17	27534	3390	42590394
Bradycardia	19.46	14.42	16	27535	85468	42508316
Macular oedema	19.26	14.42	17	27534	3552	42590232
Therapy change	19.16	14.42	18	27533	4077	42589707
Cardio-respiratory arrest	19.10	14.42	7	27544	58629	42535155
Gastric ischaemia	18.94	14.42	5	27546	60	42593724
Therapy cessation	18.64	14.42	41	27510	20409	42573375
Retinal detachment	18.56	14.42	22	27529	6503	42587281
Haemorrhage	18.46	14.42	8	27543	60555	42533229
Hyperglycaemia	18.13	14.42	68	27483	45791	42547993
Overdose	18.05	14.42	25	27526	105239	42488545
Gastrointestinal haemorrhage	18.00	14.42	22	27529	97704	42496080
Therapeutic drug monitoring analysis incorrectly performed	17.75	14.42	7	27544	318	42593466
Papillary thyroid cancer	17.63	14.42	9	27542	754	42593030
Somnolence	17.47	14.42	41	27510	141064	42452720
Renal pain	17.08	14.42	16	27535	3611	42590173
Ileus	17.03	14.42	38	27513	19101	42574683
Sepsis	16.82	14.42	69	27482	199265	42394519
Microsporidia infection	16.72	14.42	10	27541	1142	42592642
Oedema peripheral	16.48	14.42	40	27511	136036	42457748
Interstitial lung disease	16.28	14.42	16	27535	78446	42515338
Product confusion	16.24	14.42	6	27545	228	42593556
Prerenal failure	16.03	14.42	13	27538	2420	42591364
Agitation	15.97	14.42	11	27540	64303	42529481
Cholecystitis chronic	15.82	14.42	9	27542	936	42592848
Product dose omission in error	15.73	14.42	23	27528	8331	42585453
Aspartate aminotransferase increased	15.71	14.42	16	27535	77147	42516637
Vitamin B12 decreased	15.69	14.42	11	27540	1647	42592137
Diabetic ketosis	15.47	14.42	6	27545	261	42593523
Respiratory distress	15.40	14.42	4	27547	41816	42551968
Hepatic failure	15.32	14.42	3	27548	38097	42555687
Hypovolaemia	15.29	14.42	27	27524	11458	42582326
Electrolyte depletion	15.09	14.42	6	27545	279	42593505
Cardiac failure	14.93	14.42	29	27522	106827	42486957
Confusional state	14.78	14.42	57	27494	167540	42426244
Dysmetria	14.50	14.42	8	27543	785	42592999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Optic ischaemic neuropathy	1031.41	11.96	276	64946	3871	110520206
Vomiting	1007.47	11.96	1865	63357	908810	109615267
Nausea	1003.57	11.96	2224	62998	1233466	109290611
Pancreatitis	735.16	11.96	534	64688	92999	110431078
Euglycaemic diabetic ketoacidosis	645.65	11.96	247	64975	11376	110512701
Diabetic ketoacidosis	591.45	11.96	346	64876	41712	110482365
Impaired gastric emptying	355.13	11.96	168	65054	13107	110510970
Glycosylated haemoglobin increased	341.73	11.96	198	65024	23421	110500656
Pancreatitis acute	283.37	11.96	255	64967	60019	110464058
Diarrhoea	278.72	11.96	1366	63856	1138139	109385938
Weight decreased	273.39	11.96	746	64476	467311	110056766
Lactic acidosis	263.87	11.96	299	64923	92512	110431565
Inappropriate schedule of product administration	261.39	11.96	447	64775	203190	110320887
Eructation	250.09	11.96	135	65087	13922	110510155
Dehydration	227.23	11.96	506	64716	279005	110245072
Blood glucose increased	222.57	11.96	329	64893	132167	110391910
Pancreatic carcinoma	221.32	11.96	127	65095	14745	110509332
Cholelithiasis	220.00	11.96	227	64995	63195	110460882
Obstructive pancreatitis	218.44	11.96	63	65159	1178	110522899
Decreased appetite	201.91	11.96	678	64544	475168	110048909
Hypoglycaemia	177.53	11.96	276	64946	115828	110408249
Ketoacidosis	168.70	11.96	93	65129	9994	110514083
Constipation	168.06	11.96	528	64694	357258	110166819
Cholecystitis acute	163.67	11.96	107	65115	15675	110508402
Product use in unapproved indication	162.64	11.96	606	64616	446771	110077306
Pneumonia	149.06	11.96	179	65043	876535	109647542
Blood glucose decreased	146.98	11.96	129	65093	29359	110494718
Synovitis	143.05	11.96	4	65218	274088	110249989
Abdominal pain	136.95	11.96	632	64590	512357	110011720
Allodynia	129.19	11.96	48	65174	2035	110522042
Product communication issue	127.56	11.96	50	65172	2456	110521621
Neutropenia	125.47	11.96	33	65189	374587	110149490
Cholecystitis	124.56	11.96	111	65111	25771	110498306
Suicidal ideation	120.11	11.96	206	65016	93731	110430346
Bile duct stone	119.18	11.96	63	65159	6226	110517851
Pancreatitis necrotising	115.41	11.96	59	65163	5442	110518635
Systemic lupus erythematosus	113.07	11.96	10	65212	254328	110269749
Pemphigus	112.44	11.96	3	65219	214567	110309510
Diabetic retinopathy	110.58	11.96	50	65172	3514	110520563
Glossodynia	109.73	11.96	5	65217	221999	110302078
Diabetes mellitus inadequate control	109.46	11.96	110	65112	29665	110494412
Anaemia	107.07	11.96	99	65123	546987	109977090
Weight loss poor	106.86	11.96	38	65184	1419	110522658
Arthropathy	104.88	11.96	21	65201	287501	110236576
Illness	104.79	11.96	180	65042	81991	110442086
Stomatitis	102.28	11.96	18	65204	270224	110253853
Pericarditis	101.93	11.96	7	65215	219107	110304970
Drug ineffective	99.52	11.96	511	64711	1520029	109004048
Injection site pain	99.00	11.96	279	64943	177643	110346434
Death	98.44	11.96	163	65059	698706	109825371
Biliary colic	95.56	11.96	49	65173	4548	110519529
Medullary thyroid cancer	94.71	11.96	25	65197	331	110523746
Febrile neutropenia	93.38	11.96	35	65187	316732	110207345
Duodenal ulcer perforation	91.22	11.96	3	65219	177697	110346380
Thrombocytopenia	91.05	11.96	46	65176	348839	110175238
Wound	90.06	11.96	15	65207	234422	110289655
Lipase increased	87.71	11.96	79	65143	18593	110505484
Flatulence	86.78	11.96	129	65093	52020	110472057
Joint swelling	85.60	11.96	81	65141	442764	110081313
Abdominal distension	83.53	11.96	260	64962	174843	110349234
Swelling	83.37	11.96	52	65170	350989	110173088
General physical health deterioration	83.12	11.96	77	65145	425218	110098859
Folliculitis	82.12	11.96	4	65218	167649	110356428
Counterfeit product administered	81.15	11.96	21	65201	256	110523821
Treatment failure	81.09	11.96	31	65191	277203	110246874
Dermatitis atopic	80.67	11.96	87	65135	25454	110498623
Infusion related reaction	80.59	11.96	64	65158	381098	110142979
Helicobacter infection	78.57	11.96	8	65214	181869	110342208
Toxicity to various agents	77.43	11.96	102	65120	480453	110043624
Wrong technique in product usage process	76.37	11.96	163	65059	87185	110436892
Intestinal obstruction	75.07	11.96	122	65100	53105	110470972
Hunger	73.96	11.96	47	65175	6557	110517520
Increased appetite	73.59	11.96	65	65157	14912	110509165
Disease progression	73.54	11.96	26	65196	244008	110280069
Abnormal loss of weight	72.48	11.96	55	65167	10202	110513875
Pancytopenia	71.03	11.96	18	65204	209595	110314482
Drug titration error	70.47	11.96	29	65193	1618	110522459
Vision blurred	70.45	11.96	201	65021	128821	110395256
Blindness unilateral	70.31	11.96	53	65169	9733	110514344
Heart sounds	69.64	11.96	26	65196	1117	110522960
Pyrexia	69.17	11.96	284	64938	897981	109626096
Pancreatic carcinoma metastatic	68.55	11.96	38	65184	4126	110519951
Exposure during pregnancy	68.25	11.96	9	65213	167415	110356662
Drug dose titration not performed	67.73	11.96	25	65197	1040	110523037
COVID-19	67.51	11.96	305	64917	244755	110279322
Dizziness	67.47	11.96	668	64554	697525	109826552
Malignant neoplasm progression	67.42	11.96	11	65211	174556	110349521
Therapeutic product effect decreased	67.11	11.96	30	65192	244286	110279791
Acute kidney injury	66.35	11.96	618	64604	634812	109889265
Completed suicide	66.21	11.96	30	65192	242351	110281726
Drug hypersensitivity	65.64	11.96	104	65118	453986	110070091
Glomerular filtration rate decreased	65.34	11.96	83	65139	28873	110495204
Fibromyalgia	63.32	11.96	12	65210	170897	110353180
Drug intolerance	62.73	11.96	89	65133	406423	110117654
Impaired healing	62.71	11.96	19	65203	196698	110327379
Prolonged expiration	61.93	11.96	26	65196	1526	110522551
Confusional state	60.76	11.96	115	65107	468565	110055512
Starvation ketoacidosis	58.78	11.96	17	65205	321	110523756
Food craving	58.68	11.96	27	65195	1976	110522101
Respiratory failure	58.27	11.96	27	65195	215305	110308772
Depressed mood	57.26	11.96	117	65105	60692	110463385
Product dose omission in error	57.22	11.96	70	65152	23442	110500635
Oedematous pancreatitis	57.07	11.96	25	65197	1629	110522448
Mesenteric panniculitis	57.04	11.96	19	65203	581	110523496
Musculoskeletal pain	56.00	11.96	19	65203	183004	110341073
Suspected counterfeit product	55.27	11.96	20	65202	786	110523291
Sleep disorder due to a general medical condition	54.78	11.96	105	65117	52007	110472070
Throat clearing	53.99	11.96	33	65189	4300	110519777
Leukopenia	53.96	11.96	11	65211	148780	110375297
Glycosylated haemoglobin abnormal	52.77	11.96	17	65205	467	110523610
Depressive symptom	52.68	11.96	42	65180	8372	110515705
Ketosis	52.50	11.96	24	65198	1730	110522347
Diabetic ketosis	52.35	11.96	20	65202	916	110523161
Papillary thyroid cancer	52.05	11.96	28	65194	2866	110521211
Thyroid mass	51.39	11.96	34	65188	5079	110518998
Blindness	50.81	11.96	83	65139	36276	110487801
Retinopathy	50.80	11.96	32	65190	4397	110519680
Post cholecystectomy syndrome	50.53	11.96	19	65203	833	110523244
Sleep disorder due to general medical condition, insomnia type	50.23	11.96	3	65219	105640	110418437
Colitis ischaemic	50.08	11.96	57	65165	17693	110506384
Drug abuse	49.96	11.96	21	65201	177390	110346687
Oedema peripheral	49.66	11.96	73	65149	328587	110195490
Adenocarcinoma pancreas	49.59	11.96	25	65197	2238	110521839
Visual impairment	48.61	11.96	182	65040	134246	110389831
Nasal congestion	47.83	11.96	147	65075	98135	110425942
Musculoskeletal stiffness	46.47	11.96	58	65164	279764	110244313
Abdominal pain upper	46.11	11.96	358	64864	348753	110175324
Sensitive skin	45.56	11.96	28	65194	3684	110520393
Irritable bowel syndrome	45.35	11.96	20	65202	164195	110359882
Product dispensing error	45.29	11.96	52	65170	16293	110507784
Lung disorder	45.08	11.96	25	65197	180022	110344055
Skin laxity	44.95	11.96	11	65211	105	110523972
Glomerular filtration rate increased	44.13	11.96	22	65200	1923	110522154
Myelosuppression	43.90	11.96	3	65219	94337	110429740
Vitamin B12 increased	42.99	11.96	22	65200	2033	110522044
Infection	42.56	11.96	94	65128	362106	110161971
Flank pain	42.53	11.96	60	65162	23070	110501007
Bursitis	42.41	11.96	12	65210	129906	110394171
Platelet count decreased	42.35	11.96	44	65178	230399	110293678
Oedema	42.20	11.96	37	65185	209939	110314138
Mobility decreased	41.78	11.96	47	65175	237375	110286702
Incorrect dose administered	41.43	11.96	145	65077	103496	110420581
Food aversion	41.38	11.96	20	65202	1635	110522442
Prescription drug used without a prescription	40.00	11.96	30	65192	5466	110518611
Wound infection	39.75	11.96	5	65217	96460	110427617
Contraindicated product administered	39.63	11.96	53	65169	248214	110275863
Hypersensitivity	39.61	11.96	115	65107	403883	110120194
Electric shock	39.49	11.96	20	65202	1808	110522269
Blister	37.88	11.96	47	65175	227329	110296748
Vitreous haemorrhage	37.65	11.96	27	65195	4593	110519484
Ill-defined disorder	37.53	11.96	23	65199	156830	110367247
Hospitalisation	37.47	11.96	175	65047	142318	110381759
Pleural effusion	37.32	11.96	30	65192	177679	110346398
Cardio-respiratory arrest	37.25	11.96	11	65211	115825	110408252
Nephrolithiasis	36.96	11.96	104	65118	66108	110457969
Inflammation	36.53	11.96	36	65186	193202	110330875
Blood immunoglobulin A increased	36.36	11.96	18	65204	1550	110522527
Cholecystectomy	36.22	11.96	38	65184	10771	110513306
Night sweats	35.93	11.96	17	65205	133966	110390111
Haemoglobin decreased	35.87	11.96	57	65165	248670	110275407
Rheumatoid arthritis	35.82	11.96	77	65145	299536	110224541
White blood cell count decreased	35.57	11.96	50	65172	229340	110294737
Delirium	34.90	11.96	18	65204	135007	110389070
Surgery	34.88	11.96	76	65146	41207	110482870
Cellulitis gangrenous	34.65	11.96	12	65210	414	110523663
Intervertebral discitis	33.67	11.96	30	65192	6960	110517117
Diabetic neuropathy	33.64	11.96	30	65192	6969	110517108
Ileus	33.63	11.96	63	65159	30666	110493411
Postmenopausal haemorrhage	33.59	11.96	18	65204	1828	110522249
Substance use	33.58	11.96	20	65202	2486	110521591
Exposure via skin contact	33.39	11.96	40	65182	13107	110510970
Facial wasting	32.73	11.96	8	65214	76	110524001
Thyroid cancer	32.61	11.96	28	65194	6186	110517891
Vitreous detachment	32.45	11.96	20	65202	2645	110521432
Granulocyte count increased	32.38	11.96	18	65204	1965	110522112
Vomiting projectile	32.37	11.96	19	65203	2299	110521778
Incorrect dose administered by device	32.34	11.96	29	65193	6785	110517292
Gastrooesophageal reflux disease	32.28	11.96	199	65023	179777	110344300
Alopecia	32.10	11.96	109	65113	364644	110159433
Blood cholesterol increased	32.05	11.96	37	65185	184748	110339329
Respiration abnormal	32.01	11.96	34	65188	9775	110514302
Bradycardia	31.73	11.96	27	65195	155490	110368587
Aspartate aminotransferase	31.35	11.96	14	65208	955	110523122
Prescribed overdose	30.68	11.96	7	65215	87574	110436503
Retching	30.64	11.96	51	65171	22631	110501446
Live birth	30.15	11.96	3	65219	69481	110454596
Neutrophil count decreased	29.97	11.96	17	65205	120924	110403153
Product administration interrupted	29.74	11.96	35	65187	11257	110512820
Glycosylated haemoglobin decreased	29.51	11.96	13	65209	859	110523218
Blood glucose abnormal	29.10	11.96	37	65185	12879	110511198
Pancreatic enlargement	29.04	11.96	10	65212	339	110523738
Hyperglycaemia	28.94	11.96	113	65109	84977	110439100
Impaired quality of life	28.54	11.96	58	65164	29959	110494118
Rheumatoid factor increased	28.48	11.96	18	65204	2487	110521590
Vaccination site pain	28.30	11.96	11	65211	528	110523549
Hypovolaemia	28.30	11.96	48	65174	21626	110502451
Myoglobinuria	28.19	11.96	14	65208	1214	110522863
Throat irritation	27.84	11.96	82	65140	53470	110470607
Hypophagia	27.76	11.96	81	65141	52545	110471532
Therapy cessation	27.57	11.96	73	65149	44784	110479293
Feeding disorder	27.49	11.96	47	65175	21315	110502762
Stress	27.41	11.96	129	65093	105219	110418858
Asthma	27.33	11.96	246	64976	250045	110274032
Appetite disorder	26.93	11.96	31	65191	9738	110514339
Product availability issue	26.91	11.96	28	65194	7862	110516215
Liver injury	26.21	11.96	30	65192	150383	110373694
Osteoarthritis	26.19	11.96	42	65180	182581	110341496
Peripheral swelling	26.10	11.96	136	65086	403898	110120179
Injection site discharge	25.90	11.96	14	65208	1446	110522631
Cholelithiasis migration	25.75	11.96	4	65218	0	110524077
Therapy non-responder	25.69	11.96	33	65189	157274	110366803
Renal pain	25.15	11.96	30	65192	9787	110514290
Interstitial lung disease	25.15	11.96	27	65195	139307	110384770
Grip strength decreased	25.08	11.96	8	65214	80166	110443911
Gastrointestinal disorder	25.00	11.96	235	64987	241717	110282360
Overdose	24.80	11.96	64	65158	233730	110290347
Small intestinal obstruction	24.64	11.96	57	65165	32156	110491921
Upper-airway cough syndrome	24.63	11.96	38	65184	15819	110508258
Hiccups	24.58	11.96	34	65188	12835	110511242
Dactylitis	24.54	11.96	20	65202	4113	110519964
Oropharyngeal pain	24.52	11.96	150	65072	135126	110388951
Pancreatic failure	24.50	11.96	16	65206	2338	110521739
C-reactive protein increased	24.41	11.96	58	65164	217861	110306216
Psoriatic arthropathy	23.98	11.96	50	65172	196711	110327366
Gastrointestinal haemorrhage	23.79	11.96	38	65184	165480	110358597
Anion gap abnormal	23.65	11.96	11	65211	825	110523252
Post-traumatic stress disorder	23.56	11.96	24	65198	6572	110517505
Epilepsy	23.55	11.96	15	65207	100194	110423883
Hypoxia	23.48	11.96	25	65197	129490	110394587
Diabetic metabolic decompensation	23.47	11.96	19	65203	3870	110520207
Therapy change	23.10	11.96	29	65193	9968	110514109
Hepatic enzyme increased	23.04	11.96	104	65118	320788	110203289
Pulmonary fibrosis	23	11.96	16	65206	102026	110422051
Vitamin B12 deficiency	22.97	11.96	29	65193	10026	110514051
Hyperlipasaemia	22.91	11.96	13	65209	1476	110522601
Somnolence	22.83	11.96	94	65128	297355	110226722
Carpal tunnel decompression	22.75	11.96	11	65211	900	110523177
Joint noise	22.67	11.96	21	65201	5122	110518955
Drug reaction with eosinophilia and systemic symptoms	22.66	11.96	10	65212	82085	110441992
Cardiac failure congestive	22.34	11.96	34	65188	150966	110373111
Hypercholesterolaemia	22.18	11.96	13	65209	90824	110433253
Neuropathy vitamin B12 deficiency	22.09	11.96	7	65215	182	110523895
Distributive shock	22.04	11.96	22	65200	5882	110518195
Hepatic steatosis	21.88	11.96	71	65151	48760	110475317
Necrotising myositis	21.80	11.96	14	65208	1988	110522089
Respiratory arrest	21.79	11.96	4	65218	58295	110465782
Prescribed underdose	21.30	11.96	6	65216	65168	110458909
Therapeutic response shortened	21.16	11.96	51	65171	29532	110494545
Device difficult to use	21.14	11.96	39	65183	18766	110505311
Cholangitis	21.10	11.96	36	65186	16299	110507778
Liver disorder	21.07	11.96	32	65190	142211	110381866
Seizure	20.91	11.96	64	65158	221121	110302956
Maculopathy	20.88	11.96	16	65206	3011	110521066
Gait inability	20.86	11.96	30	65192	136346	110387731
Eye haemorrhage	20.85	11.96	30	65192	11744	110512333
Hyperphagia	20.78	11.96	17	65205	3514	110520563
Injection site bruising	20.72	11.96	72	65150	51191	110472886
Optic neuritis	20.62	11.96	29	65193	11118	110512959
Pharyngeal swelling	20.35	11.96	30	65192	12002	110512075
Pancreatic mass	20.27	11.96	13	65209	1842	110522235
Vitamin D deficiency	20.26	11.96	38	65184	18514	110505563
Mycobacterium ulcerans infection	20.15	11.96	6	65216	126	110523951
Pneumonitis	20.07	11.96	10	65212	76521	110447556
Drug effect less than expected	19.80	11.96	23	65199	7297	110516780
Hypoglycaemic unconsciousness	19.72	11.96	11	65211	1209	110522868
Drug dependence	19.65	11.96	3	65219	50017	110474060
Hyperthyroidism	19.40	11.96	49	65173	29212	110494865
Gastric ischaemia	19.39	11.96	5	65217	60	110524017
Benign pancreatic neoplasm	19.39	11.96	5	65217	60	110524017
Intentional dose omission	19.33	11.96	39	65183	20041	110504036
Intussusception	19.32	11.96	12	65210	1609	110522468
Pigmentation lip	19.31	11.96	3	65219	0	110524077
Neoplasm progression	19.24	11.96	7	65215	64588	110459489
Depression	19.22	11.96	278	64944	317057	110207020
Rales	19.17	11.96	44	65178	24695	110499382
Idiopathic intracranial hypertension	19.11	11.96	17	65205	3935	110520142
Irregular sleep phase	18.79	11.96	6	65216	160	110523917
Urethral caruncle	18.62	11.96	5	65217	71	110524006
Electrolyte depletion	18.40	11.96	8	65214	512	110523565
Visual field defect	18.33	11.96	26	65196	10046	110514031
Sleep apnoea syndrome	18.29	11.96	59	65163	40388	110483689
Skin burning sensation	18.23	11.96	40	65182	21785	110502292
Syncope	18.14	11.96	191	65031	202345	110321732
Amylase increased	18.06	11.96	29	65193	12490	110511587
Eyelid injury	18.06	11.96	6	65216	182	110523895
Pregnancy	18.05	11.96	4	65218	51063	110473014
Autoimmune disorder	18.03	11.96	8	65214	65475	110458602
Coma	17.96	11.96	26	65196	117843	110406234
Urine albumin/creatinine ratio increased	17.89	11.96	10	65212	1103	110522974
Agranulocytosis	17.89	11.96	7	65215	61753	110462324
Blood pressure systolic decreased	17.86	11.96	30	65192	13411	110510666
Haemorrhage	17.82	11.96	22	65200	106670	110417407
Cytomegalovirus infection	17.82	11.96	5	65217	54439	110469638
Erectile dysfunction	17.82	11.96	36	65186	18520	110505557
International normalised ratio increased	17.78	11.96	15	65207	86757	110437320
Off label use	17.67	11.96	1066	64156	1499119	109024958
Pulmonary oedema	17.62	11.96	20	65202	100639	110423438
Adverse event	17.59	11.96	23	65199	108786	110415291
Exostosis	17.51	11.96	3	65219	45953	110478124
Macular oedema	17.37	11.96	21	65201	6945	110517132
Terminal insomnia	17.36	11.96	12	65210	1926	110522151
Injection site vesicles	17.32	11.96	17	65205	4454	110519623
Blood glucose fluctuation	17.26	11.96	22	65200	7676	110516401
Lack of satiety	17.23	11.96	3	65219	3	110524074
Product dose omission issue	17.21	11.96	276	64946	321506	110202571
Lipoma	17.14	11.96	16	65206	3939	110520138
Oesophageal pain	17.14	11.96	18	65204	5107	110518970
Hepatotoxicity	17.06	11.96	8	65214	63392	110460685
Menstruation irregular	17.01	11.96	19	65203	5778	110518299
Intentional product use issue	16.82	11.96	82	65140	247824	110276253
Therapy interrupted	16.80	11.96	66	65156	49756	110474321
Vitamin B12 decreased	16.76	11.96	18	65204	5239	110518838
Osteoporosis	16.74	11.96	16	65206	87136	110436941
Chronic kidney disease	16.72	11.96	89	65133	76202	110447875
Cholelithotomy	16.70	11.96	5	65217	107	110523970
Optic atrophy	16.68	11.96	13	65209	2508	110521569
Product confusion	16.62	11.96	6	65216	234	110523843
Osteonecrosis of jaw	16.49	11.96	4	65218	48013	110476064
Influenza	16.35	11.96	162	65060	168939	110355138
Blepharospasm	16.25	11.96	6	65216	54845	110469232
Eyelid haematoma	16.20	11.96	5	65217	119	110523958
Back injury	16.18	11.96	4	65218	47395	110476682
Dyspepsia	16.13	11.96	178	65044	190787	110333290
White blood cells urine positive	16.08	11.96	21	65201	7503	110516574
Cytokine release syndrome	15.88	11.96	11	65211	70295	110453782
Accidental exposure to product	15.87	11.96	65	65157	49943	110474134
Metabolic acidosis	15.86	11.96	107	65115	99637	110424440
Sedation	15.61	11.96	11	65211	69672	110454405
Contraindicated product prescribed	15.55	11.96	12	65210	2281	110521796
Neurotoxicity	15.55	11.96	3	65219	42204	110481873
Microsporidia infection	15.52	11.96	10	65212	1429	110522648
Pancreatitis chronic	15.50	11.96	16	65206	4449	110519628
Paranasal sinus discomfort	15.47	11.96	19	65203	6386	110517691
Contusion	15.36	11.96	78	65144	233283	110290794
Onychoclasis	15.16	11.96	20	65202	7217	110516860
Urine calcium/creatinine ratio increased	15.10	11.96	5	65217	150	110523927
Retinal haemorrhage	15.09	11.96	23	65199	9478	110514599
Disseminated intravascular coagulation	15.07	11.96	3	65219	41283	110482794
Retinal detachment	15.05	11.96	25	65197	11075	110513002
Drug dose omission by device	14.95	11.96	29	65193	14487	110509590
Foot deformity	14.88	11.96	5	65217	48475	110475602
Lack of injection site rotation	14.83	11.96	9	65213	1157	110522920
Injection site haemorrhage	14.78	11.96	48	65174	32980	110491097
Blood triglycerides increased	14.76	11.96	39	65183	23887	110500190
Extra dose administered	14.66	11.96	26	65196	12133	110511944
Symptom recurrence	14.62	11.96	16	65206	4756	110519321
Abortion spontaneous	14.60	11.96	49	65173	34233	110489844
Umbilical hernia repair	14.56	11.96	5	65217	168	110523909
Sarcopenia	14.50	11.96	9	65213	1205	110522872
Lower respiratory tract infection	14.49	11.96	84	65138	243022	110281055
Sciatica	14.46	11.96	20	65202	92379	110431698
Underdose	14.28	11.96	10	65212	63544	110460533
Lower limb fracture	14.27	11.96	14	65208	75334	110448743
Cholecystitis infective	14.25	11.96	14	65208	3673	110520404
Injury	14.24	11.96	55	65167	177210	110346867
Dry mouth	14.23	11.96	65	65157	199883	110324194
Stevens-Johnson syndrome	14.11	11.96	5	65217	46896	110477181
High frequency ablation	14.10	11.96	6	65216	364	110523713
Coeliac disease	14.07	11.96	4	65218	43183	110480894
Pancreatic neuroendocrine tumour	14.05	11.96	8	65214	915	110523162
Respiratory distress	13.99	11.96	12	65210	68862	110455215
Device programming error	13.96	11.96	6	65216	373	110523704
Chronic obstructive pulmonary disease	13.93	11.96	27	65195	109131	110414946
Product substitution error	13.91	11.96	4	65218	74	110524003
Productive cough	13.85	11.96	115	65107	114190	110409887
Rash maculo-papular	13.82	11.96	14	65208	74208	110449869
Haemoptysis	13.82	11.96	13	65209	71341	110452736
Head injury	13.72	11.96	56	65166	42961	110481116
Sudden visual loss	13.71	11.96	4	65218	78	110523999
Ascites	13.63	11.96	21	65201	92787	110431290
Gastroenteritis	13.57	11.96	52	65170	38748	110485329
Aspartate aminotransferase abnormal	13.55	11.96	13	65209	3312	110520765
Sunburn	13.50	11.96	15	65207	4533	110519544
Pancreatic disorder	13.49	11.96	14	65208	3920	110520157
Hepatitis toxic	13.40	11.96	17	65205	5904	110518173
Retinal vascular thrombosis	13.39	11.96	5	65217	215	110523862
Abdominal wall disorder	13.36	11.96	6	65216	415	110523662
Product label issue	13.32	11.96	8	65214	1010	110523067
Papilloedema	13.30	11.96	19	65203	7390	110516687
Retinal vein occlusion	13.27	11.96	14	65208	3993	110520084
Fluid retention	13.22	11.96	22	65200	94285	110429792
Ketonuria	13.12	11.96	9	65213	1426	110522651
Therapeutic drug monitoring analysis incorrectly performed	13.12	11.96	7	65215	705	110523372
Inability to afford medication	13.07	11.96	14	65208	4062	110520015
Pemphigoid	13.06	11.96	33	65189	19674	110504403
Diabetic retinal oedema	13.05	11.96	6	65216	438	110523639
Intrusive thoughts	13.03	11.96	7	65215	714	110523363
Hypertension	13.00	11.96	217	65005	509867	110014210
Palmar-plantar erythrodysaesthesia syndrome	13.00	11.96	4	65218	41021	110483056
Foreign body in throat	13.00	11.96	8	65214	1055	110523022
Orthopaedic procedure	12.99	11.96	5	65217	234	110523843
Follicular thyroid cancer	12.97	11.96	4	65218	95	110523982
Eosinophil count abnormal	12.92	11.96	8	65214	1066	110523011
Therapy partial responder	12.90	11.96	3	65219	37058	110487019
Lipoedema	12.79	11.96	5	65217	244	110523833
Product preparation error	12.78	11.96	23	65199	10856	110513221
Hepatic failure	12.76	11.96	13	65209	68726	110455351
Plasma cell myeloma	12.75	11.96	11	65211	62925	110461152
Early satiety	12.72	11.96	10	65212	1953	110522124
Hypoglycaemic coma	12.70	11.96	16	65206	5517	110518560
Gait disturbance	12.69	11.96	104	65118	278104	110245973
Diabetes mellitus	12.59	11.96	101	65121	99280	110424797
Hyponatraemia	12.55	11.96	76	65146	217577	110306500
Acute respiratory distress syndrome	12.45	11.96	8	65214	53190	110470887
Dysarthria	12.38	11.96	19	65203	84102	110439975
Erythema	12.37	11.96	111	65111	291336	110232741
Cholecystitis chronic	12.35	11.96	21	65201	9479	110514598
Hypoaesthesia	12.35	11.96	122	65100	314101	110209976
Colon cancer stage II	12.34	11.96	5	65217	268	110523809
Neuroendocrine tumour	12.31	11.96	9	65213	1578	110522499
Gallbladder enlargement	12.29	11.96	10	65212	2052	110522025
Product use complaint	12.09	11.96	13	65209	3790	110520287
Nasal discharge discolouration	12.08	11.96	12	65210	3189	110520888
Dyschezia	12.08	11.96	13	65209	3794	110520283
Obesity	12.04	11.96	31	65191	113320	110410757

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10AE57	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting
ATC	A10BJ06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues
FDA CS	M0160181	Glucagon-Like Peptide 1
FDA MoA	N0000020058	Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA	D000097789	Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D019440	Anti-Obesity Agents
FDA EPC	N0000178480	GLP-1 Receptor Agonist
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:50507	appetite depressant
CHEBI has role	CHEBI:63726	neuroprotective agent
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:71196	glucagon-like peptide-1 receptor agonist
CHEBI has role	CHEBI:74518	anti-obesity agent

Related Drugs by ATC class:

A10AE Insulins and analogues for injection, long-acting 9 drugs

insulin beef insulin degludec insulin detemir insulin glargine insulin human insulin icodec insulin pork liraglutide lixisenatide

A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs

albiglutide dulaglutide exenatide liraglutide lixisenatide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Weight loss	indication	89362005
Obesity	indication	414916001	DOID:9970

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.23	acidic
pKa2	3.31	acidic
pKa3	3.71	acidic
pKa4	3.97	acidic
pKa5	4.22	acidic
pKa6	4.53	acidic
pKa7	4.76	acidic
pKa8	9.65	acidic
pKa9	12.06	acidic
pKa10	12.28	acidic
pKa11	12.41	acidic
pKa12	12.5	acidic
pKa13	12.63	acidic
pKa14	12.76	acidic
pKa15	12.95	acidic
pKa16	12.98	acidic
pKa17	13.11	acidic
pKa18	13.18	acidic
pKa19	13.24	acidic
pKa20	13.3	acidic
pKa21	13.4	acidic
pKa22	13.51	acidic
pKa23	13.61	acidic
pKa24	13.66	acidic
pKa25	13.73	acidic
pKa26	13.77	acidic
pKa27	13.83	acidic
pKa28	13.87	acidic
pKa29	13.94	acidic
pKa30	11.05	Basic
pKa31	10.45	Basic
pKa32	7.88	Basic
pKa33	5.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	DISCN	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	DISCN	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11033499	June 19, 2033	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	METHOD OF TREATING TYPE 2 DIABETES
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	DISCN	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12514822	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12239739	May 2, 2034	METHOD OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12569543	April 28, 2037	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD OF TREATING TYPE 2 DIABETES
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	11752198	Aug. 24, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	12214017	Aug. 24, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12295988	Oct. 10, 2038	METHOD OF TREATING TYPE 2 DIABETES
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	12295988	Oct. 10, 2038	METHOD OF TREATING TYPE 2 DIABETES
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	12295988	Oct. 10, 2038	METHOD OF TREATING TYPE 2 DIABETES
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	12295988	Oct. 10, 2038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	12029779	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	12551536	Oct. 10, 2038	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	11833248	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	12396953	Feb. 1, 2039	METHOD OF WEIGHT REDUCTION
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11478533	May 13, 2040	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11478533	May 13, 2040	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11478533	May 13, 2040	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11478533	May 13, 2040	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11478533	May 13, 2040	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD OF TREATING TYPE 2 DIABETES
0.25MG/0.5ML (0.25MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD OF TREATING TYPE 2 DIABETES
0.5MG/0.5ML (0.5MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD OF TREATING TYPE 2 DIABETES
1MG/0.5ML (1MG/0.5ML)	OZEMPIC	NOVO	N209637	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	TREATMENT OF SUBJECTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	TREATMENT OF SUBJECTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	TREATMENT OF SUBJECTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	TREATMENT OF SUBJECTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	REDUCTION OF THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	May 5, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	TREATMENT OF SUBJECTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD OF WEIGHT REDUCTION VIA SUBCUTANEOUS ADMINISTRATION

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	July 21, 2026	USE OF SEMAGLUTIDE 1.7 MG SUBCUTANEOUS WEEKLY AS AN ADDITIONAL MAINTENANCE DOSE
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	March 8, 2027	IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	DISCN	SOLUTION	SUBCUTANEOUS	Jan. 28, 2028	TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	Jan. 28, 2028	TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	Jan. 28, 2028	TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	Jan. 28, 2028	TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Aug. 15, 2028	TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Aug. 15, 2028	TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Aug. 15, 2028	TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Aug. 15, 2028	TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Aug. 15, 2028	TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS
1.5MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
4MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
9MG	OZEMPIC	NOVO	N213051	Dec. 9, 2024	RX	TABLET	ORAL	Oct. 17, 2028	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
1.5MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	Dec. 22, 2028	NEW PRODUCT
25MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	Dec. 22, 2028	NEW PRODUCT
4MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	Dec. 22, 2028	NEW PRODUCT
9MG	WEGOVY	NOVO	N218316	Dec. 22, 2025	RX	TABLET	ORAL	Dec. 22, 2028	NEW PRODUCT
7.2MG/0.75ML (7.2MG/0.75ML)	WEGOVY HD	NOVO	N215256	March 19, 2026	RX	SOLUTION	SUBCUTANEOUS	March 19, 2029	NEW STRENGTH

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST	IC50	9.42		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
53AXN4NNHX	UNII
4037164	VANDF
C3885068	UMLSCUI
CHEMBL2108724	ChEMBL_ID
56843331	PUBCHEM_CID
DB13928	DRUGBANK_ID
D10025	KEGG_DRUG
D000099194	MESH_DESCRIPTOR_UI
9113	INN_ID
9724	IUPHAR_LIGAND_ID
764283003	SNOMEDCT_US
764284009	SNOMEDCT_US
CHEBI:167574	CHEBI
304634	MMSL
325192	MMSL
33346	MMSL
370649	MMSL
d08688	MMSL
017424	NDDF
1991302	RXNORM
53AXN4NNHX	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1302	INJECTION, SOLUTION	0.25 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1305	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1310	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	30 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1602	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1605	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1610	INJECTION, SOLUTION	2 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1617	INJECTION, SOLUTION	2.27 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1624	INJECTION, SOLUTION	3.20 mg	SUBCUTANEOUS	NDA	32 sections
OZEMPIC	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1704	TABLET	4 mg	ORAL	NDA	29 sections
OZEMPIC	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1709	TABLET	9 mg	ORAL	NDA	29 sections
OZEMPIC	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1715	TABLET	1.50 mg	ORAL	NDA	29 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4130	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4130	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4132	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4132	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4136	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4136	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4181	INJECTION, SOLUTION	0.68 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4181	INJECTION, SOLUTION	0.68 mg	SUBCUTANEOUS	NDA	30 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4303	TABLET	3 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4303	TABLET	3 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4307	TABLET	7 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4307	TABLET	7 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4314	TABLET	14 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4314	TABLET	14 mg	ORAL	NDA	29 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4404	TABLET	4 mg	ORAL	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4409	TABLET	9 mg	ORAL	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4415	TABLET	1.50 mg	ORAL	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4425	TABLET	25 mg	ORAL	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4501	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	32 sections

Ask DrugCentral

semaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: